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Objectives: In randomized controlled trials, differences in prognostic factors 
– whether statistically significant or not – contribute to absolute differences in 
outcomes. Absolute differences are at the heart of economic evaluation. Economic 
modelling may help increase precision of incremental differences, despite ran-
domization. The objective of the present study was to describe the effect of 
economic modelling techniques on the magnitude and precision of economic 
and decision outcomes using a RCT-based economic evaluation. MethOds: An 
economic evaluation was conducted alongside a RCT (n= 350) in diagnostic inter-
ventional cardiology. Raw unadjusted total costs and QALYs were assembled at 
the individual level using resource use and EQ5D responses. For economic mod-
elling, outcomes were then conditioned according to the diagnosis and fit with 
generalized linear models, adjusting for baseline characteristics. Total costs and 
QALYs were then estimated using marginal prediction with the fitted models. 
Family and link functions were selected using the Modified Park’s and Pregibon 
Link test, respectively. Uncertainty in GLM coefficients, unit cost parameters 
and sampling were incorporated using bootstrapping and Monte Carlo meth-
ods. Results: The magnitude and direction of incremental costs were compa-
rable between the raw vs. modelled results (-£132 vs. -£204). However, precision 
increased considerably; the 95%CI reduced by 44% ([-£1772 to £817] vs. [-£1437 to 
£30]). Incremental QALYs also showed comparable magnitudes (0.013 vs -0.005), 
though the direction reversed, albeit by a non-important magnitude. As well, the 
95%CI of incremental QALYs reduced by 83% ([-0.033 to 0.060] vs. [-0.015 to 0.001]). 
Reduction in joint incremental cost-effect uncertainty was also apparent upon 
visual inspection of the cost-effectiveness plane. Decision (cost-effectiveness) 
uncertainty was comparable across the common willingness-to-pay thresholds 
(~70% at £0-£30,000/QALY). cOnclusiOns: Economic modelling can increase pre-
cision in economic outcomes and reduce uncertainty in decision making, support-
ing the results and decision arising from a raw unadjusted economic evaluation 
alongside a RCT.
CS3
Cure ModelS: ACCounting For Cured PAtientS in eConoMiC 
evAluAtionS
Othus M.1, Bansal A.2, Koepl L.1, Wagner S.3, Ramsey S.1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, 
WA, USA, 3Bristol-Myers Squibb, Washington Crossing, PA, USA
Objectives: Economic evaluations of competing interventions often estimate 
mean overall survival (OS) as a measure of intervention effect. New treatments 
offer some patients the possibility of being “cured” of their disease, in that they 
become long-term survivors whose risk of death is the same as a disease-free per-
son. Grouping cured and non-cured patients together and reporting one mean value 
for OS may provide a biased assessment of a therapy that cures a proportion of 
patients. In this study, we compared standard survival analysis versus an approach 
that accounts for the fraction of patients cured. MethOds: We used clinical trial 
data from advanced melanoma patients treated with ipilimumab (n= 137) versus 
gp100 (n= 136) and applied statistical methodology for mixture cure models. We used 
logistic regression to model the probability that a patient was cured and a Weibull 
regression model to estimate the excess mortality for non-cured patients. Both 
cured and non-cured patients were subject to background mortality not related to 
cancer; we calculated this using age- and gender-matched mortality data from US 
Social Security life tables. Results: Ignoring a cured proportion, ipilimumab had 
an estimated mean OS that was 8 months longer than gp100. Cure model analy-
sis showed that the proportion of cured patients drove this difference, with 20% 
cured on ipilimumab compared to 6% with gp100. The mean OS among non-cured 
patients was 5 months on ipilimumab versus 4 months on gp100. The mean OS 
among cured patients was 26 years on both arms. After adjusting for covariates, 
ipilimumab had an improved cure proportion compared to gp100 (OR= 2.01, 95% CI 
(1.00, 4.06)), but there were no significant differences in survival among non-cured 
patients (HR= 1.05, 95% CI (0.80, 1.38)). cOnclusiOns: This analysis supports using 
cure modeling in health economic evaluation in advanced melanoma, since it may 
reduce bias in OS estimates.
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Objectives: Methodologies and information systems associated with health 
intervention costs in Canada have evolved since the Guidance Document for the 
Costing Process was published in 1996. This document was produced to assist 
researchers undertaking economic studies of health interventions in Canada. To 
ensure this document is useful to researchers the Canadian Agency for Drugs 
and Technologies in Health (CADTH) is undertaking a major update of the docu-
ment. This presentation will provide an overview of the key changes to the 
document, based on the availability of new information sources and methodolo-
gies. MethOds: A literature review of Canadian economic evaluations published 
between 2011 to 2014 was conducted by CADTH to understand how cost infor-
mation is currently being used by researchers. In addition, CADTH conducted a 
scan of the various costing and resource use methodologies used in health care 
in Canada, and undertook discussions with researchers in health costing. Based 
on the information obtained, required revisions and additions to the Guidance 
Document were identified. Results: The updated Guidance Document con-
sists of eight sections: Pharmaceuticals, Physician Services, Hospital Services, 
Diagnostic and Investigational Services, Non-Physician Professional Services, 
Community Based Services, Informal Caregiver Costs, and Other Information. 
These categories give way to targeted subsections, for which, detailed descrip-
tions of cost components are provided, along with relevant data sources and 
guidance as to how and when researchers can apply the data. Key additions to 
this update include: the inclusion of newer methodologies (e.g., CMG+ costing, 
thresholds for reimbursement decisions, we describe a model for ensuring that 
opportunity cost is appropriately captured in the willingness-to-pay value. We 
then show how the modified model would impact upon coverage decisions which 
include an ‘end-of-life premium’. Results: We identify four broad categories of 
value premia. We characterise the importance of locating opportunity cost factors 
(including price and budget impact) outside the value framework. We then describe 
a structural process for ensuring that the value framework is applied equally to the 
identified beneficiaries of a technology and the frequently unidentified individuals 
who will bear the opportunity cost, in order to promote horizontal equity in HTA 
processes. Finally, we show how the conventional approach to incorporating value 
premia, such as the ‘end-of-life premium’, promotes inefficient and inequitable 
resource allocation decisions. cOnclusiOns: The conventional HTA model does 
not adequately reflect the social value of health care. However, naïve modifications 
to the cost-effectiveness threshold lead to both inefficient and inequitable resource 
allocation decisions. It is important that modified value frameworks are applied 
equally to the identified beneficiaries of a technology and those individuals who 
bear the opportunity cost.
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Objectives: The U.S. Agency for Healthcare Research and Quality (AHRQ) solicited 
the development of guidance for modeling and simulation studies conducted in the 
context of health technology assessment. MethOds: We updated and expanded 
existing systematic reviews of recommendations for the conduct and reporting 
of modeling and simulation studies in healthcare. We also solicited input from a 
multidisciplinary team of clinical, policy, and decision analysis experts. The Results 
of the systematic review were then discussed in person with a panel of 28 stake-
holders including patient representatives, providers and purchasers of care, payers, 
policy makers, and principal investigators. Stakeholders commented on existing 
recommendations and identified gaps, limitations, and areas for elaboration. We 
subsequently reviewed the websites of 126 health technology assessment organiza-
tions that provide guidance on the conduct and reporting of decision and simula-
tion models. We sought additional input from senior researchers with experience 
in modeling and simulation within AHRQ and its Evidence-based Practice Centers, 
and from external reviewers. Results: We developed principles and good practice 
recommendations for modeling and simulation studies conducted to enhance and 
contextualize the findings of systematic reviews. The guidance applies to struc-
tural mathematical models and simulation experiments based on such models. 
The recommendations address model identification, estimation, and evaluation, 
as well as the use of sensitivity, stability, and uncertainty analyses throughout 
model development and use. Recommendations are organized by whether they 
pertain to the model conceptualization and structure, data, consistency, or the 
interpretation and reporting of Results. We provide the rationale for each recom-
mendation, with supporting evidence or, when adequate evidence was lacking, 
best judgment. cOnclusiOns: We present systematically developed guidance for 
modeling and simulation in the context of health technology assessment. We are 
hopeful that this work will contribute to increased use of modeling and simulation 
in conjunction with systematic reviews.
reSeArCh on CoSt StudieS MethodS
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Objectives: To explain the relevance of and provide guidance for using a new cost 
metric, the National Average Drug Acquisition Cost (NADAC) for US based economic 
evaluations. The key feature of NADAC is that a single cost is reported for a unit of 
all pharmaceutically equivalent drugs. The cost is an average of the per unit cost 
paid by the current month’s national sample of retail pharmacies. MethOds: We 
propose a costing procedure and provide a detailed overview of costing for five 
diverse drugs and compare estimates to AWP, the current metric used as an estimate 
for acquisition cost. With data from 2014 and enumerated specific National Drug 
Codes (NDC) included in each estimate, we used the July cost as the base-case and 
the range observed over the year as a measure of uncertainty. For AWP we used its 
value on July 1. To eliminate the impact of obsolete NDCs we only considered the 
AWPs of NDCs that had an associated NADAC in 2014. The base-case was estimated 
as the average of AWP across equivalent NDCs and the range was the low and high 
AWP. Results: In one example, 500mg cephalexin had a NADAC of $0.09662 in July. 
This cost was based on 22 NDCs and was updated 11 times throughout the year. The 
range was [$0.08877, $0.12138] per unit. By contrast the distribution of AWPs for the 
same 22 NDCs had an average of $1.35606 and range of [$1.2259, $1.376]. In other 
drugs the ratio of NADAC and AWP ranged from 7-89%. cOnclusiOns: NADAC 
has limitations, but appears to provide a better estimate of true drug acquisition 
cost than AWP. Given the wide discrepancy observed between NADAC and AWP it 
appears using AWP, even discounted, may introduce bias in economic evaluations.
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were identified. Patients were required to have ≥ 365 day of continuous enrollment 
prior to and ≥ 730 days after the index date (date of the first claim), a claim with a 
T2DM diagnosis (ICD-9-CM 250.x0, 250.x2) and no claims for a DPP-4i medication 
prior to the index date. All-cause and diabetes-related total costs were captured over 
one-year and two-year follow-up periods. Generalized linear models with log link 
and gamma distribution were fit to compare costs between the two cohorts, control-
ling for patient baseline characteristics. Results: The final sample comprised 3,354 
saxagliptin initiators and 26,895 sitagliptin initiators. The average age of saxagliptin 
and sitagliptin initiators was 57 years old and just over 50% were males. After adjust-
ing for baseline characteristics, saxagliptin patients had significantly lower average 
all-cause medical costs over the one-year ($8,406 vs. $9,368, p< 0.0001) and two-year 
follow-up ($17,367 vs. $19,410, p< 0.0001) compared with sitagliptin patients. Total 
costs were lower for saxagliptin initiators over the one-year ($13,644 vs. $14,388, 
p= 0.0015) and two-year follow-up ($27,491 vs. $29,198, p= 0.0002). Findings were 
consistent for diabetes-related medical costs (one-year: $2,097 vs. $2,370, p< 0.0001; 
two-year: $4,312 vs. $4,753, p= 0.0003) and total diabetes-related costs (one-year: 
$4,210 vs. $4,417, p= 0.0048; two-year: $8,391 vs. $8,701, p= 0.0326). cOnclusiOns: 
Initiation of treatment with saxagliptin was associated with lower medical costs 
over one and two years compared with sitagliptin.
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Objectives: Portfolio management is commonly used to prioritize investments 
within the private sector, but is not used widely to manage public research invest-
ments due to the difficulty of defining and quantifying appropriate measures 
of risk and return. We recently developed a novel tools to estimate the risk and 
return of publicly funded cancer clinical trials. Our objective was to use these 
metrics and apply a proof of concept portfolio management approach within 
SWOG, a large cancer clinical trials cooperative group. MethOds: The sample 
portfolio included 9 randomized Phase II/III clinical trial concepts reviewed by 
SWOG between 2008-2013, of which 5 were approved and 4 were not. Risk was 
defined as the probability of insufficient accrual (< 50% of target) and measured 
using a previously validated prediction model. Value of Information methods were 
used to estimate societal return, defined both as the population-level expected 
health benefits (clinical return) or clinical and economic benefits (net return) of 
acquiring additional information to inform a decision and measured. We com-
pared the risk-adjusted expected returns of the observed portfolio of approved 
trials to hypothetical alternative portfolios in which different trials might have 
been funded. Results: The clinical return of SWOG’s sample portfolio was valued 
at $11.3 billion. A hypothetical alternative portfolio of trials requiring 200 fewer 
patients than the observed portfolio was expected to have a clinical return of $26.3 
billion. The net return of SWOG’s observed sample portfolio was $2.7 billion. An 
alternative hypothetical portfolio that includes four trials and requires 400 fewer 
patients than the observed portfolio was expected to have a net return of approxi-
mately $9.6 billion. cOnclusiOns: A portfolio management approach appears 
to be a feasible and potentially useful response to the Institute of Medicine’s call 
for more systematic approaches to prioritize trials concepts within the cancer 
clinical trials cooperative groups.
heAlth teChnology ASSeSSMent StudieS
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leSSon leArned FroM PuBliShed htAS And StudieS
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
Objectives: Ultra orphan therapies are indicated for rare diseases affecting less 
than a few thousand patients. The annual and lifetime per patient cost of these 
treatments have generated controversy and policy questions regarding cost effec-
tiveness and reimbursement. The objective of this analysis was to review all avail-
able cost effectiveness studies and develop lessons for policy development for ultra 
orphan therapies. MethOds: Fifteen European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) approved ultra orphan drugs were identified and 
reviewed for their published cost effectiveness through studies in peer-reviewed 
journals and Health Technology Assessments (HTAs). Data was collected for: (1) 
Product (2) Indication (3) Model design and assumptions (4) Author of the analy-
sis (manufacturer, HTA or academic group) (5) Cost effectiveness results and (5) 
Sensitivity analysis results. All cost effectiveness ratios were converted to 2013 US 
dollar amounts using historical currency conversion rates. Results: For fifteen 
EMA and FDA approved ultra orphan therapies, eight cost effectiveness studies 
were identified for seven products (50%). Four of these studies were conducted by 
the sponsor (as part of the HTA submission), two were conducted by HTAs and two 
were from academic groups. All models were developed for a life time horizon. 
In the base case scenario, the median base case incremental cost effectiveness 
ratio (ICER) was $591,200 per quality adjusted life years (QALYs) (range: $391,120 
to $7,425,000). The sensitivity analyses results had a median ICER of $1,958,674 per 
QALY, with a maximum ICER of $10,395,000. All reported ICERs exceeded the maxi-
mum accepted thresholds for end of life care therapies. cOnclusiOns: Review of 
cost effectiveness studies for ultra orphan therapies shows that none were able to 
show ICERs within typical thresholds. These results suggest a need for new policy 
regarding acceptable threshold, or type of models for assessing the cost effective-
ness of ultra orphan therapies.
patient costing), more details on the various cost components and sources of 
data, and considerations for costing based on economic evaluation considera-
tions (e.g. setting, perspective). cOnclusiOns: The 2nd edition of the Guidance 
Document aims to better assist Canadian researchers in appropriately identifying, 
measuring, and sourcing the types of costs and resources relevant for economic 
evaluations.
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Objectives: The Centers for Disease Control and Prevention reported that the costs 
attributable to Chronic Obstructive Pulmonary Disease (COPD) are projected to be 
$49.0 billion by 2020. This retrospective claims analysis characterized and compared 
Medicare beneficiaries with high and low healthcare resource utilization (HCRU) as 
a means to inform the drivers of this large economic burden. MethOds: Medicare 
beneficiaries with a COPD diagnosis in 2012 were identified in the Centers for 
Medicare and Medicaid Services (CMS) claims databases. HCRU groups were defined 
based on the total payment amount across the inpatient, outpatient and physician 
office settings; high and low utilizers represented the top and bottom quartiles, 
respectively. The utilization groups were compared across patient demographics, 
comorbidities and HCRU using t-tests. A classification tree was fitted to identify the 
patient risk factors that were the biggest drivers of differences in HCRU. Results: 
Overall, 257,752 COPD patients were identified, with 64,438 patients in each of 
the high and low utilization groups. The mean (95% confidence interval) payment 
amounts for high and low utilizers were $54,176 ($53,847, $54,506) and $1,131 ($1,126, 
$1,136), respectively. On average, high utilizers had a significantly (p< 0.001) higher 
number of claims, longer length of stay, higher Charlson Comorbidity Index (CCI) 
score and more complicated comorbid respiratory conditions and medical proce-
dures (102, 19, 6, 60%, 21%) relative to low utilizers (16, 0, 2, 23%, 4%). The classifica-
tion tree identified the most important risk factors in differentiating high and low 
utilizers as CCI score, comorbid anemia, COPD complexity, comorbid pneumonia 
and heart failure. cOnclusiOns: HCRU among COPD Medicare patients varied 
greatly, with high utilizers tending to be sicker across all comorbidity measures. The 
classification tree analysis indicated that comorbidities such as anemia, pneumonia 
and heart failure are more highly associated with HCRU than demographic factors, 
such as age, gender and race.
he2
exPlAining the exCeSS hoMe heAlth CAre uSe And exPenditureS 
AMong elderly MediCAre BeneFiCiArieS with PArkinSon’S diSeASe
Bhattacharjee S.1, Metzger A.2, Tworek C.1, Wei W.3, Pan X.4, Sambamoorthi U.2
1The University of Arizona, Tucson, AZ, USA, 2West Virginia University, Morgantown, WV, USA, 
3Sanofi US LLC, Bridgewaters, NJ, USA, 4Evidera LLC, Lexington, MA, USA
Objectives: This study compared home healthcare use and expenditures 
among elderly Medicare beneficiaries with and without Parkinson’s disease 
(PD) and analyzed the extent to which individual-level factors contribute to 
the excess home healthcare use and expenditures among individuals with 
PD. MethOds: A retrospective, observational, cohort study was conducted using 
Medicare 5% sample claims database with baseline (year 2006) and follow-up 
(year 2007) period. The study sample included elderly (age > 65 years) fee-for-
service Medicare beneficiaries continuously enrolled in Medicare Part A and B for 
2006 and 2007. Elderly Medicare beneficiaries with PD were identified based on 
the ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical 
Modification) codes of 332.xx during baseline. All the independent variables were 
measured during baseline. The dependent variables (home healthcare use and 
expenditures) were measured in 2007. Logistic regressions and Ordinary Least 
Square regressions were used to assess the association of PD with home health 
use and expenditures respectively. Post regression non-linear and linear decom-
position techniques were used to understand the extent to which differences 
in home healthcare use and expenditures among elderly Medicare beneficiar-
ies with and without PD can be explained by individual-level factors. Results: 
Elderly Medicare beneficiaries with PD had 13.3 percentage point higher home 
healthcare use, of which 27.5% were explained by differences in characteristics 
between the two groups. Among home healthcare users, those with PD had greater 
expenditures ($6,792) compared to those without PD ($4,965). Only 18% of the 
difference in home healthcare expenditures were explained by differences in 
characteristics between the two groups. Baseline resource use and comorbidi-
ties explained majority of the differences in home healthcare use and expendi-
tures. cOnclusiOns: These findings underscore the importance of developing 
interventions such as using appropriate evidence based co-management of multi-
ple chronic conditions and need of interdisciplinary team collaboration to provide 
better care.
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Objectives: To compare all-cause and diabetes-related utilization and costs fol-
lowing initiation of the dipeptidyl peptidase-4 inhibitors saxagliptin or sitagliptin 
in the treatment of type 2 diabetes (T2DM). MethOds: Patients aged 18+ with ≥ 1 
prescription claim for saxagliptin or sitagliptin between 1/1/2009 and 1/31/2012 in 
the Truven Health MarketScan Commercial and Medicare Supplemental databases 
